Analysts will be keenly tracking the top-line performance of Amgen’s (AMGN) established products, as they continue to see revenue erosion, when the firm reports its Q3 earnings on November 3, after ...

Amgen Inc.’s Q3 is near. Explore EPS growth, pipeline momentum, valuation, and dividend yield to see why it offers good ...

Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the ...

Amgen appears safe, but the current valuation above $450/share may prove expensive by Q3 2026. Click here to read an analysis of AMGN stock now.

By Deena Beasley Nov 2 (Reuters) - The recent failure of a Novartis experimental heart drug in a large trial raised questions ...

Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.

Amgen reports 10% annual revenue growth and a 2.1% yield, while Novo Nordisk faces 2026 revenue declines amid pricing wars.

Amgen stock enters the third-quarter reporting week with higher spending in focus. Growth brands must offset biosimilar ...

Drug developers have designed therapies to reduce the cholesterol-carrying molecule Lp(a), which is associated with heart ...

WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today ...

Arcutis Biotherapeutics, Inc. announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer ...